SEC Company Response from Damora Therapeutics, (DMRA) — Oct 23, 2020
Damora Therapeutics, Inc.
Date: Oct. 23, 2020 · CIK: 0001800315 · Accession: 0001193125-20-275431
AI Filing Summary & Sentiment
File numbers found in text: 333-249369
Letter
Division of Corporation Finance Office of Life Sciences Susan Block Kristin Lochhead Kate Tillan Re: Galecto, Inc. Registration Statement on Form S-1, as amended (Registration No. 333-249369)
Dear Mr. Field:
In connection with the above-referenced Registration Statement, as amended, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Galecto, Inc. that the effective date of the Registration Statement, as amended, be accelerated so that it will be declared effective at 4:00 p.m. Eastern Time on October 27, 2020, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, please be advised that we and the other prospective underwriters have distributed approximately 2,000 copies of the preliminary prospectus dated October 22, 2020 through the date hereof, to underwriters, dealers, institutions and others.
In connection with the preliminary prospectus distribution for the above-referenced issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement in Rule 15c2-8(b) under the Securities Exchange Act of 1934, as amended.
Very truly yours,
BOFA SECURITIES, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP October 23, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Donald Field Susan Block Kristin Lochhead Kate Tillan Re: Galecto, Inc. Registration Statement on Form S-1, as amended (Registration No. 333-249369) Dear Mr. Field: In connection with the above-referenced Registration Statement, as amended, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Galecto, Inc. that the effective date of the Registration Statement, as amended, be accelerated so that it will be declared effective at 4:00 p.m. Eastern Time on October 27, 2020, or as soon thereafter as practicable. Pursuant to Rule 460 under the Act, please be advised that we and the other prospective underwriters have distributed approximately 2,000 copies of the preliminary prospectus dated October 22, 2020 through the date hereof, to underwriters, dealers, institutions and others. In connection with the preliminary prospectus distribution for the above-referenced issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement in Rule 15c2-8(b) under the Securities Exchange Act of 1934, as amended. Very truly yours, BOFA SECURITIES, INC. SVB LEERINK LLC CREDIT SUISSE SECURITIES (USA) LLC As Representatives of the several underwriters [SIGNATURE PAGE FOLLOWS] BOFA SECURITIES, INC. By: /s/ Michele A.H. Allong Name: Michele A.H. Allong Title: Authorized Signatory SVB LEERINK LLC By: /s/ Gabriel Cavazos Name: Gabriel Cavazos Title: Managing Director CREDIT SUISSE SECURITIES (USA) LLC By: /s/ Rebecca Kotkin Name: Rebecca Kotkin Title: Director As representatives of the several underwriters. [Signature Page to Acceleration Request Letter]